+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost-effectiveness analysis of early versus late total hip replacement in Italy

Cost-effectiveness analysis of early versus late total hip replacement in Italy

Value in Health 16(2): 267-279

To assess the cost-effectiveness of early primary total hip replacement (THR) for functionally independent older adult patients with osteoarthritis (OA) versus 1) nonsurgical therapy followed by THR once the patient has progressed to a functionally dependent state ("delayed THR") and 2) nonsurgical therapy alone ('medical therapy'), from the Italian National Health Service perspective. Individual patient data and evidence from published literature on disease progression, economic costs and THR outcomes in OA, including utilities, perioperative mortality rates, prosthesis survival, and costs of prostheses, THR, rehabilitation, follow-up, revision, and nonsurgical management, combined with population life tables, were synthesized in a Markov model of OA. The model represents the lifetime experience of a patient cohort following their treatment choice, discounting costs and benefits (quality-adjusted life-years) at 3% annually. At age 65 years, the incremental cost per quality-adjusted life-year of THR over delayed THR was €987 in men and €466 in women; the figures for delayed THR versus medical therapy were €463 and €82, respectively. Among 80-year-olds, early THR is (extended) dominant. With gradual utility loss after primary THR, delaying surgery may be more appealing in women than in men in their 50s, because longer female life expectancy implies longer latter periods of low health-related quality of life (HRQOL) with early THR. THR is cost-effective. Patients' HRQOL benefits forgone with delayed THR are worth more than the costs it saves to the Italian National Health Service. This analysis might help to explain women's consistently lower HRQOL by the time of primary operation.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036742689

Download citation: RISBibTeXText

PMID: 23538178

DOI: 10.1016/j.jval.2012.10.020

Related references

Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. Thrombosis and Haemostasis 110(5): 987-994, 2013

Telerehabilitation after total knee replacement in Italy: cost-effectiveness and cost-utility analysis of a mixed telerehabilitation-standard rehabilitation programme compared with usual care. Bmj Open 6(5): E009964, 2016

Early assessment of the likely cost-effectiveness of a new technology: A Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. International Journal of Technology Assessment in Health Care 22(2): 191-202, 2006

Early Versus Late Ketoanalogs Supplementation In Patients With Chronic Kidney Disease In Taiwan - A Cost-Effectiveness Analysis. Value in Health 17(7): A470, 2014

Modeling the cost-effectiveness for cement-less and hybrid prosthesis in total hip replacement in Emilia Romagna, Italy. Journal of Surgical Research 169(2): 227-233, 2011

An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy. Value in Health 11(3): 354-364, 2007

Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Pharmacoeconomics 5(3): 227-237, 1994

Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). Biology of Blood and Marrow Transplantation 19(2): S130-S131, 2013

Cost-effectiveness of enoxaparin versus warfarin for the prevention of deep vein thrombosis following total hip replacement. Blood 82(10 Suppl. 1): 613A, 1993

Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Cmaj 150(7): 1083-1090, 1994

Total hip replacement. A cost-effectiveness analysis. Ugeskrift for Laeger 150(5): 284-287, 1988

Cost-effectiveness study of early versus late parenteral nutrition in critically ill children (PEPaNIC): preplanned secondary analysis of a multicentre randomised controlled trial. Critical Care 22(1): 4, 2018

Cost-effectiveness of cemented versus cementless total hip arthroplasty. A Markov decision analysis based on implant cost. Journal of Orthopaedics and Traumatology 9(1): 23-28, 2008

Cost utility modeling of early vs late total knee replacement in osteoarthritis patients. Osteoarthritis and Cartilage 24(12): 2069-2076, 2016

Cost-effectiveness of total disc replacement versus multidisciplinary rehabilitation in patients with chronic low back pain: a Norwegian multicenter RCT. Spine 39(1): 23-32, 2014